Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. J of Skin [Internet]. 2019 Nov. 9 [cited 2025 Jun. 8];3:S29. Available from: https://skin.dermsquared.com/skin/article/view/756